Cargando…

Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and the fifth most common cause of female cancer death in the United States. Although important advances in surgical and chemotherapeutic strategies over the last three decades have significantly improved the median survival o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konstantinopoulos, Panagiotis A., Matulonis, Ursula A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858677/ https://www.ncbi.nlm.nih.gov/pubmed/24377084 http://dx.doi.org/10.3389/fonc.2013.00296

Ejemplares similares

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer
por: Penson, Richard T, et al.
Publicado: (2023)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2018)

Patient-Derived Xenografts Are a Reliable Preclinical Model for the Personalized Treatment of Epithelial Ovarian Cancer
por: Chen, Jiayu, et al.
Publicado: (2021)

Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction
por: Chiang, Ying-Cheng, et al.
Publicado: (2021)

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure
por: Lee, Elizabeth K., et al.
Publicado: (2019)

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
por: Choi, Young Eun, et al.
Publicado: (2014)

Evaluation of the potential of ultrasound-mediated drug delivery for the treatment of ovarian cancer through preclinical studies
por: Wang, Yi-Chao, et al.
Publicado: (2022)

Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib
por: Eismann, Julia, et al.
Publicado: (2019)

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
por: Lee, Elizabeth K., et al.
Publicado: (2019)

Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation
por: Geier, Brian, et al.
Publicado: (2015)

A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs
por: Pan, Elizabeth, et al.
Publicado: (2020)

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
por: Strickland, Kyle C., et al.
Publicado: (2016)

Mouse models of epithelial ovarian cancer for preclinical studies
por: Karakashev, Sergey, et al.
Publicado: (2021)

Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer
por: Zeligs, Kristen P., et al.
Publicado: (2020)

A Translational Model to Improve Early Detection of Epithelial Ovarian Cancers
por: Gockley, Allison, et al.
Publicado: (2022)

Cannabinoids as anticancer drugs: current status of preclinical research
por: Hinz, Burkhard, et al.
Publicado: (2022)

Patient-Derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment
por: Scott, Clare L., et al.
Publicado: (2013)

Evidence of Differential Effects of Vitamin D Receptor Variants on Epithelial Ovarian Cancer Risk by Predicted Vitamin D Status
por: Prescott, Jennifer, et al.
Publicado: (2014)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Identification of Novel Drug Candidate for Epithelial Ovarian Cancer via In Silico Investigation and In Vitro Validation
por: Zou, Dan, et al.
Publicado: (2021)

Epithelial–Mesenchymal Transition in Ovarian Carcinoma
por: Davidson, Ben, et al.
Publicado: (2012)

c-MYC and Epithelial Ovarian Cancer
por: Reyes-González, Jeyshka M., et al.
Publicado: (2021)

Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models
por: Zheng, Qingfan, et al.
Publicado: (2022)

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer
por: Konstantinopoulos, Panagiotis A, et al.
Publicado: (2008)

Modeling Radioimmune Response—Current Status and Perspectives
por: Friedrich, Thomas, et al.
Publicado: (2021)

Preclinical Models of Malignant Mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2020)

Preclinical Models of Neuroblastoma—Current Status and Perspectives
por: Krawczyk, Ewa, et al.
Publicado: (2023)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

The Coming of Age of Preclinical Models of MDS
por: Liu, Wei, et al.
Publicado: (2022)

Preclinical modeling of lower-grade gliomas
por: Tang, Lilly W., et al.
Publicado: (2023)

Editorial: Advances in Epithelial Ovarian Cancer: Model Systems, Microenvironmental Influences, Therapy, and Origins
por: Howell, Viive Maarika, et al.
Publicado: (2015)

Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research
por: Clark, James, et al.
Publicado: (2022)

Survival prognosis model for elderly women with epithelial ovarian cancer based on the SEER database
por: Zhou, Yingping, et al.
Publicado: (2023)

Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

Editorial: Preclinical models and emerging technologies to study the effects of the tumor microenvironment on cancer heterogeneity and drug resistance
por: Adriani, Giulia, et al.
Publicado: (2023)

Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
por: Heo, Eun Jin, et al.
Publicado: (2017)

The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
por: Blanquart, Christophe, et al.
Publicado: (2020)

Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair–Deficient Endometrial Cancer
por: Gulhan, Doga C., et al.
Publicado: (2020)

Development of a Mouse Model of Menopausal Ovarian Cancer
por: Smith, Elizabeth R., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ev2gjbo97lgtaupklh2sudnvns